Amgen (AMGN): financials, SEC filings and peers
Amgen (AMGN) is a biotechnology company in the Health Care sector of the S&P 500, headquartered in Thousand Oaks, California.
It was founded in 1980 and joined the S&P 500 on January 2, 1992.
Its fiscal year ends in December, and its shares trade on the Nasdaq.
In its SEC filings it is classified as “Biological Products, (No Diagnostic Substances)”.
Amgen at a glance
- Revenue (12 months)
- $38.9B
- Revenue growth
- +8.2%
- Operating margin
- 32.4%
- Net income (12 months)
- $9.4B
- Free cash flow (12 months)
- $9.6B
- Cash
- $13.2B
- Debt
- $54.0B
- Diluted EPS (12 months)
- $17.25
Twelve months to September 30, 2026, from the 10-Q filed November 4, 2026.
Latest twelve months
Over the twelve months to September 30, 2026, Amgen reported revenue of $38.9 billion, up 8.2% from a year earlier.
Its operating margin was 32.4%, up 8.3 percentage points from a year earlier: for every $100 of sales, about $32 was left as operating profit.
Net income was $9.4 billion (24.1% of revenue), 34.1% higher than a year earlier.
Operating cash flow was $12.0 billion and capital spending $2.5 billion, leaving free cash flow of $9.6 billion (24.6% of revenue).
At the end of the period it held $13.2 billion in cash and $54.0 billion in debt, a net debt position of $40.8 billion.
Five-year trend
- Revenue went from $25.4 billion in fiscal 2020 to $36.8 billion in fiscal 2025, about 7.6% a year.
- Revenue has grown for 5 fiscal years in a row.
- Operating margin narrowed from 35.9% to 24.7% over the same years.
- Free cash flow was positive in each of the last 6 fiscal years.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $26.0B | $26.3B | $28.2B | $33.4B | $36.8B |
| Revenue growth | 2.2% | 1.3% | 7.1% | 18.6% | 10.0% |
| Operating margin | 29.4% | 36.3% | 28.0% | 21.7% | 24.7% |
| Net income | $5.9B | $6.6B | $6.7B | $4.1B | $7.7B |
| Free cash flow | $8.4B | $8.8B | $7.4B | $10.4B | $8.1B |
| Diluted EPS | $10.28 | $12.11 | $12.49 | $7.56 | $14.23 |
Fiscal years as reported in Amgen’s 10-K filings. Free cash flow is operating cash flow minus capital spending.
Recent SEC filings
- 10-Q filed November 4, 2026 — quarterly report
- 8-K filed November 3, 2026 — Earnings results
- 8-K filed October 27, 2026 — Executive or director change
- 10-Q filed August 5, 2026 — quarterly report
- 8-K filed August 4, 2026 — Earnings results
- 8-K filed July 31, 2026
- 8-K filed May 20, 2026 — Shareholder vote results
- 8-K filed May 19, 2026 — Executive or director change
Companies like Amgen
Other S&P 500 companies in Biotechnology:
- ABBVAbbVieNorth Chicago, Illinois
- BIIBBiogenCambridge, Massachusetts
- GILDGilead SciencesFoster City, California
- INCYIncyteWilmington, Delaware
- MRNAModernaCambridge, Massachusetts
- REGNRegeneron PharmaceuticalsTarrytown, New York
- VRTXVertex PharmaceuticalsBoston, Massachusetts
More from Health Care
Questions about Amgen
Is Amgen's revenue growing?
Yes. Revenue for the twelve months to September 30, 2026 was $38.9 billion, up 8.2% from a year earlier, according to its SEC filings.
Is Amgen profitable?
Yes. It earned $9.4 billion in net income over the twelve months to September 30, 2026, a net margin of 24.1%.
Does Amgen have more cash or more debt?
At September 30, 2026 it had $13.2 billion in cash and $54.0 billion in debt, so more debt than cash.
When did Amgen last file financial results?
Its latest quarterly report (10-Q) was filed with the SEC on November 4, 2026.
Which companies are similar to Amgen?
In the S&P 500, Amgen is grouped in Biotechnology within the Health Care sector. AbbVie (ABBV), Biogen (BIIB), Gilead Sciences (GILD), Incyte (INCY), Moderna (MRNA) are in the same group.
Understand the numbers
Source: Amgen’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved November 11, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.